OmniAb SPAC Presentation Deck
OMNIAB INTELLECTUAL PROPERTY ADVANTAGE
PARTNERS FILING PATENTS ON OMNIAB-DERIVED ANTIBODIES CREATE DURABLE
ROYALTY STREAMS AND A LENGTHY INTELLECTUAL PROPERTY TAIL
ā
We maintain a broad intellectual property estate with
multiple long duration patent families covering each
major element of our technology platform
Licenses are structured so that royalties are linked to the
patents for the antibodies discovered with OmniAb,
thereby creating a lengthy coverage tail
>60 patent filings by our partners claiming an
OmniAb-derived antibody as primary invention, with expiries up to 2041
Over 300 patents issued worldwide
Antibody Patent Applications
filed by Partners
70
60
50
40
30
20
10
0
2014
2015
2016
2017
2018
2019
2020
2021
21
OmniAbView entire presentation